Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker
Authors:
Open Access
- 26 January 2009
- journal article
- other
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 3 (2) , 113-121
Abstract
Background: The long-term effects of the angiotensin-receptor blocker candesartan, the angiotensin-converting enzyme inhibitor enalapril or their combination have been incompletely studied in a large cohort of patients with heart failure not treated with beta-blockers. The objective of this study was to investigate the changes in neurohormones and LV volumes and ejection fraction in patients treated with enalapril, candesartan, or enalapril plus candesartan without concomitant beta-blocker therapy. Methods: Three hundred and ninety-two patients from the RESOLVD pilot study not treated with a beta-blocker at baseline or at any time during the trial were analyzed. Norepinephrine, endothelin-1, big endothelin-1, angiotensin-II, aldosterone, N-terminal proANP, BNP, and radionuclide angiography were measured before and after 43 weeks of treatment with candesartan alone (n = 162), or enalapril alone (n = 45), or candesartan plus enalapril (n = 185). Endpoints were assessed at baseline and after 43 weeks of therapy. Results: LV end-diastolic and end-systolic volumes increased significantly at 43 weeks in all groups except for patients treated with enalapril plus candesartan. BNP decreased at 43 weeks only in patients receiving dual angiotensin-II suppression (-6.1 ± 37.8 pmol/l). Angiotensin-II levels were significantly increased in patients treated with candesartan (+23.6 ± 47.1 pg/ml; p<0.05). Conclusion: We conclude that angiotensin-II modulation, with enalapril and candesartan, without concomitant utilization of beta-blocker lead to a decrease in BNP and an attenuation of the increase in LV end-diastolic and end-systolic volumes without a reversal of this process in the long term.Keywords
This publication has 31 references indexed in Scilit:
- The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT)Journal of Cardiac Failure, 2006
- Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarctionAmerican Heart Journal, 2005
- Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: Results of the Optimal Trial in Myocardial Infarction with Angiotensin II antagonist losartan (optimaal) echocardiographic substudyAmerican Heart Journal, 2004
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- β-blockers, angiotensin II, and ACE inhibitors in patients with heart failureThe Lancet, 2001
- Angiotensin Blockade Inhibits Increased JNKs, AP-1 and NF- B DNA-binding Activities in Myocardial Infarcted RatsJournal of Molecular and Cellular Cardiology, 2001
- Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT1 receptorsBritish Journal of Pharmacology, 1999
- The Antihypertensive Effect and Tolerability of Candesartan Cilexetil, a New Generation Angiotensin II Antagonist, in Comparison with LosartanBlood Pressure, 1998
- Plasma endothelin during upright tilt: relevance for orthostatic hypotension?The Lancet, 1991
- Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shockBiochemical and Biophysical Research Communications, 1989